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Abstract 
Background: Misoprostol, a prostaglandin E1 analogue with its uterotonic properties 
has entered as an integral part of management of the third stage of labour, helping to 
prevent postpartum haemorrhage (PPH). 
 
Objective: To assess evidence on the effectiveness of misoprostol compared to a 
placebo for the prevention and treatment of postpartum haemorrhage. 
   
Methods: Databases searched included; MEDLINE, Google Scholar and Cochrane 
Central Register of Controlled Trials (CENTRAL).  Other sources were also searched.  
All articles were screened for methodological quality by two reviewers independently by 
standardized instrument.  Data was entered in Review Manger 5.1 software for analysis. 
 
Results: Three Misoprostol studies were included (2346 participants), Oral (2 trials) and 
sublingual (1 trial).  Misoprostol has shown not to be effective in reducing PPH (RR 
0.65: 95% CI 0.40-1.06).  Only one trial reported on need for blood transfusion (RR 
0.14; 95% CI 0.02-1.15).  Misoprostol use is associated with significant increases in 
shivering (RR 2.75; 95% CI 2.26-3.34) and pyrexia (RR 5.34; 95% CI 2.86-9.96) than 
with placebo.  No maternal deaths were reported in included trials.  Compared to 
placebo, misoprostol was coupled with less hysterectomies and additional used of 
uterotonics (RR 0.45; 95%CI 0.21-0.96) compared to placebo. 
 
Conclusion: Results of this review shows that the use of misoprostol in combination 
with some components of active management was not associated with any significant 
reduction in incidence of PPH.  However oral administration showed a significant 
reduction in incidence of PPH.  For its use for treatment of postpartum haemorrhage, 
there is a need for research focus in optimal dose and route of administration for a 
clinically significant effect and acceptable side effects.  
Keywords 
Misoprostol, prevention, postpartum haemorrhage, randomized controlled trials. 
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Opsomming 
Agtergrond:  Misoprostol, 'n prostaglandien E1 analoog met sy uterotonic eienskappe 
het ingeskryf as' n integrale deel van die bestuur van die derde stadium van kraam, help 
postpartum bloeding (PPH) te voorkom. 
 
Doelwit:  Om bewyse oor die effektiwiteit van Misoprostol in vergelyking met 'n placebo 
vir die voorkoming en behandeling van postpartum bloeding te evalueer. 
 
Metodes:  Databases gesoek ingesluit, Medline, CINHAL, Google Scholar en Cochrane 
Sentrale Register van gecontroleerde studies (Sentraal).  Ander bronne is ook 
deursoek.  Alle artikels is gekeur vir die metodologiese kwaliteit deur twee beoordelaars 
onafhanklik deur die gestandaardiseerde instrument.  Data is opgeneem in Review 
Manger 5.1 sagteware vir ontleding. 
 
Hoof Resultate:  Drie Misoprostol studies were ingesluit (2346 deelnemers). Mondeling 
(2 proe) en sublinguale (1 verhoor). Misoprostol het getoon nie doeltreffend te wees in 
die vermindering van PPH (RR 0,65: 95% CI 0,40-1,06). Slegs een verhoor berig oor 
die noodsaaklikheid vir 'n bloedoortapping (RR 0,14, 95% CI 0,02-1,15).  Misoprostol 
gebruik word geassosieer met 'n aansienlike toename in bewing (RR 2,75, 95% CI 2,26-
3,34) en koors (RR 5,34, 95% CI 2,86-9,96) as met' n placebo. Geen moederlike 
sterftes is aangemeld in proewe.  In vergelyking met placebo, was Misoprostol tesame 
met minder hysterectomies en addisionele gebruik van uterotonics (RR 0,45, 95% 
CI,21-,96) in vergelyking met placebo. 
 
Gevolgtrekking:  Resultate van hierdie studie toon dat die gebruik van Misoprostol in 
kombinasie met 'n paar komponente van aktiewe bestuur is wat nie verband hou met' n 
beduidende afname in die voorkoms van PPH.  Vir die gebruik vir die behandeling van 
postpartum bloeding, daar is 'n behoefte vir navorsing fokus in die optimale dosis en die 
roete van administrasie vir' n klinies beduidende uitwerking en aanvaarbare newe-
effekte. 
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MISOPROSTOL FOR PREVENTION AND TREATMENT OF POSTPARTUM 
HAEMORRHAGE: A SYSTEMATIC REVIEW 
 
Kabelo Monicah Olefile  
Oswell Khondowe 
Doreen M’Rithaa 
Abstract  
Background: Misoprostol, a prostaglandin E1 analogue with its uterotonic properties 
has entered as an integral part of management of the third stage of labour, helping to 
prevent postpartum haemorrhage (PPH). 
Objective: To assess evidence on the effectiveness of misoprostol compared to a 
placebo for the prevention and treatment of postpartum haemorrhage.   
Methods: Databases searched included; MEDLINE, Google Scholar and Cochrane 
Central Register of Controlled Trials (CENTRAL).  Other sources were also searched.  
All articles were screened for methodological quality by two reviewers independently by 
standardized instrument.  Data was entered in Review Manger 5.1 software for analysis. 
Results: Three Misoprostol studies were included (2346 participants). Oral (2 trials) and 
sublingual (1 trial).  Misoprostol has shown not to be effective in reducing PPH (RR 
0.65: 95% CI 0.40-1.06).  Only one trial reported on need for blood transfusion (RR 
0.14; 95% CI 0.02-1.15).  Misoprostol use is associated with significant increases in 
shivering (RR 2.75; 95% CI 2.26-3.34) and pyrexia (RR 5.34; 95% CI 2.86-9.96) than 
with placebo.  No maternal deaths were reported in included trials.  Compared to 
placebo, misoprostol was coupled with less hysterectomies and additional used of 
uterotonics (RR 0.45; 95%CI 0.21-0.96) compared to placebo. 
 
Conclusion: Results of this review shows that the use of misoprostol in combination 
with some components of active management was not associated with any significant 
reduction in incidence of PPH.  However oral administration showed a significant 
reduction in incidence of PPH.  For its use for treatment of postpartum haemorrhage, 
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there is a need for research focus in optimal dose and route of administration for a 
clinically significant effect and acceptable side effects.  
Background  
Maternal mortality continues to be one of the most serious and intractable health 
problems for women of reproductive age in low-income countries (Tsu & Shane, 
2004:83).  Reduction of the maternal mortality ratio by three quarters by 2015 is the 
target for one of the eight Millennium Development Goals (MDGs) set by 189 countries 
in 2000 (Rosenfield, Maine & Freedman, 2006:1333).  Postpartum hemorrhage (PPH), 
the leading cause of maternal deaths worldwide, has received international attention 
among medical and research communities for decades.  World Health Organization 
(WHO, 2007) defines PPH as postpartum blood loss of 500ml or more from the genital 
tract.  However in populations with a higher prevalence of anemia, blood loss of less 
than 500ml has been noted to have several physical consequences (McCormick, 
Sanghvi, Kinzie & McIntosh, and 2002:267).  
 
Magnitude of the problem:  The maternal mortality ratio in developing countries is 450 
maternal deaths per 100 000 live births versus nine in developed countries (WHO, 
2007).  An estimated 358,000 maternal deaths occurred worldwide in 2008 (UNICEF, 
2010).  According to UNICEF (2010), out of 1000 maternal deaths that occur due to 
causes including severe bleeding after child birth, 560 deaths occurred in Sub Saharan 
Africa and 300 in South Asia compared to five in high-income countries.  According to 
the Millennium Development Goals (MDGs) report (2010), there was significant 
progress in maternal mortality ratios (MMRs) in developing regions, the average annual 
percentage decline in the global MMR was 2.3%, short of the MDG target of 5.5%.  
However in year 2008, there was an estimated 1.7 % annual rate of decline in sub-
Saharan Africa, where levels of mortality are highest, is slower than in any other region.  
According to UNICEF (2010) maternal mortality ratio in South Africa was 410 in 100 000 
in 2008.  
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The Saving Mothers reports (2009:12) states that obstetric haemorrhage is the third 
most common cause of maternal death in South Africa (SA), accounting for 491 (12.4%) 
of all maternal deaths during the  period of 2005 to 2007.  In SA, sub-standard care 
remained a major problem, contributing to over 40% of deaths for every level of care.  
This includes failure to carry out essential steps of prescribed protocols or serious 
delays in doing so, and lack of appropriate skills.  According to Fawcus and Moodley 
(2011), it is fundamental that all levels of care are able to deal with the emergency 
management of PPH and are aware of the factors required to prevent it.  This requires 
sufficient facilities, supplies and skilled staff.  Major improvements in the implementation 
of the health system and appropriate training of doctors and midwives at all levels of 
care are essential if deaths from this preventable cause of maternal mortality are to be 
reduced.  
 
Description of the condition 
Post partum haemorrhage is defined as excessive vaginal bleeding (blood loss greater 
than 500 ml) within 24 hours following delivery (WHO, 2005).  There is no better or 
more definitive explanation for PPH. McCormick , Sanghvi, Kinzie and McIntosh ( 2002) 
state that, a more accurate definition of PPH is any blood loss that results in a 
physiological change (e.g., low blood pressure) that threatens the woman’s life. 
Bleeding after delivery is controlled by a combination of contraction of the myometrium, 
which constricts the blood vessels supplying the placental bed and local decidual 
hemostatic factors including tissue factor, type-1 plasminogen activator inhibitor and 
systemic coagulation factors (Lockwood & Schatz, 1996).  Major etiologies of and risk 
factors of PPH include the following: uterine atony, coagulation defects, retained 
placenta, birth trauma and vaginal or cervical tears (Lockwood, Krikun & Schatz, 1999). 
Other risk factors include macrosomic baby, twin pregnancy, prolonged or augmented 
labour and antepartum haemorrhage.  Despite the detection of risk factors, primary.  
PPH often occurs unpredictably in low-risk women. 
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Complications 
The most imperative consequences of PPH include hypovolaemic shock, disseminated 
intravascular coagulopathy (DIC), fatigue and adult respiratory distress syndrome.  In 
low-income countries, poor nutritional status, deficient access to treatment, inadequate 
intensive care and blood bank facilities are additional causative factors that lead to the 
elevated morbidity and mortality rates in some settings. 
 
Description of intervention  
Weeks and Faúndes (2007) delineate misoprostol as a prostaglandin E1-analogue with 
uterotonic properties that can be administered orally, sublingually, vaginally and rectally.  
Sublingual administration of misoprostol achieves the uppermost serum peak 
absorption and takes the shortest time to reach the peak level, in comparison with other 
routes of administration (Tang, Schweer, Seybert, Lee & Ho, 2002).  Initially, 
misoprostol was introduced as treatment for peptic ulcers.  Misoprostol has been used 
to treat a variety of obstetrical problems, including uterine atony, postpartum 
haemorrhage, induction of labour, and induction of abortion (Hofmeyr, Walraven, 
Gülmezoglu, Maholwana, Alfirevic & Villar, 2005).  Ng, Chan, Sin, Tang, Cheung and 
Yuen (2001) observed that misoprostol when given postpartum is known to cause only 
mild side effects (shivering and pyrexia).  However, misoprostol is a sustainable drug for 
use in developing countries for the treatment of an assortment of obstetrical 
complications (Winikoff, Dabash, Durocher, Darwish, Nguyen, León, et al. 2010).  
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How misoprostol might work 
The key management of PPH involves rapid recognition and diagnosis of the condition, 
restoration of circulating blood volume with a simultaneous search for the cause.  
According to WHO (2000), injectable oxytocin and ergometrine have been 
recommended for routine use in the active management of the third stage of labour.  
However, administration of an injection requires skills and sterile equipment for safe 
administration.  Oxytocin may be inactivated if exposed to high ambient temperatures 
and requires cold-chain storage. WHO (2000) regard oxytocin as the gold standard for 
treatment of post-partum haemorrhage.  Mousa and Alfirevic (2007) state that 
misoprostol is highly effective in inducing uterine contractions and has been proposed 
as a low-cost, easy-to-use alternative.   
 
Oxytocin is usually the preferred drug where active management of the third stage of 
labour is practiced (Langenbach, 2006: Gülmezoglu, Villar, Ngoc, Piaggio, Carroli, 
Adetoro, Abdel-Aleem et al. 2001).  Zuberi, Durocher, Sikander, Baber, Blum and 
Walraven (2008), advocated for the availability of misoprostol in community-based 
settings with limited access to conventional injectable uterotonics.  Misoprostol has an 
important role to play in hospital settings and its adjunct use should continue to be 
explored for its potential in quick, safe and effective controlling of postpartum bleeding, 
averting recourse to more invasive procedures and preventing more severe maternal 
morbidity (Zuberi et al. 2008).  Ng et al. (2001) observed that misoprostol when given 
postpartum is known to root only mild side effects (shivering and pyrexia) of which are 
dose dependent.  
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Significance of this research 
Several systematic reviews have been done to assess the effectiveness of misoprostol 
in the prevention of PPH (Hofmeyer et al, 2007; Gülmezoglu, Forna, Villar & Hofmeyr 
2011; Mousa & Alfirevic, 2009).  In the above mentioned reviews, reviewers looked at 
the likelihood that misoprostol can be used as first-line of therapy in absence of 
injectable uterotonics.  However some studies have shown that misoprostol promises as 
an adjunct treatment and its use should continue to be explored for its life-saving 
potential in the care of women experiencing PPH (Zuberi, 2008).  In meta analysis of 
these previous reviews, studies included compared misoprostol to a placebo in addition 
to other uterotonics.  Does this imply that misoprostol cannot be used alone for 
management and prevention of PPH?  Is the real uterotonic effect of Misoprostol not 
affected by other uterotonics combined with it?  A systematic review is needed to collate 
and assess the effectiveness of misoprostol compared to a placebo, without additional 
uterotonics for the prevention and treatment of PPH where other uterotonic agents are 
not feasible.  
 
Objectives  
The objective of this systematic review was to assess evidence on the effectiveness of 
misoprostol compared to placebo for the prevention and treatment of postpartum 
haemorrhage.   
 
Specific objectives: The specific objectives were to determine the effectiveness of 
misoprostol in preventing and treating blood loss of ≥ 500ml and to investigate maternal 
mortality, severe morbidity, pyrexia, shivering, need for additional uterotonics in 
association with use of misoprostol compared with placebo for prevention of postpartum 
haemorrhage.   
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Criteria for considering studies for this review 
 
Type of studies:  Randomized controlled trials (RCT) that assessed the effectiveness 
of misoprostol compared to placebo in the prevention and treatment of postpartum 
haemorrhage during vaginal delivery were included in this review.  
Types of participants:  Studies that included women in labour with anticipated vaginal 
deliveries and women at low risk of postpartum haemorrhage were considered for 
inclusion.  Low risk of PPH was defined as having no history of postpartum 
haemorrhage, with singleton pregnancies.  Studies that included women with caesarean 
section and women with anaemia were excluded as such participants are considered to 
be high risk pregnancy and vulnerable to have PPH. 
 
Types of interventions:  Intervention considered for this review was Misoprostol 
versus placebo or non- treatment for prevention and treatment of PPH up to third stage 
of labour.  Active management of third stage of labour (AMTSL) found to be useful and 
promoted by WHO was included as part of the interventions.  AMTSL is defined as use 
of a uterotonic drug immediately following delivery of the fetus, controlled cord traction 
and early cord clamping and cutting.  All studies irrespective of dose or route (oral, 
sublingual or rectal) of misoprostol were considered for this review.  Studies that 
compared Misoprostol to a placebo in addition to other uterotonics were excluded. 
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Types of outcomes measures  
 
Primary outcomes 
Outcomes of interest in trials: 
• Blood loss of 500ml 
• Maternal mortality 
 
Secondary outcomes 
• Severe morbidity (hysterectomy/surgery, need for blood transfusion and manual 
removal of placenta). 
• Pyrexia (temperature of more than 38°C or more) and shivering. 
• Need for additional use of uterotonics.   
 
For the purpose of this review, maternal morbidity was defined as the need for blood 
transfusion, manual removal of placenta, hysterectomy and major surgery and pyrexia 
was defined as temperature of more than 38oC. 
 
Search methods for identification of studies 
Electronic search: A thorough comprehensive search for relevant studies was 
conducted on the following databases:  MEDLINE, CINHAL, Google Scholar and 
Cochrane Central Register of Controlled Trials (CENTRAL).  Subsequent MESH 
(Medical Subject Headings) terms used were; misoprostol, ergot preparations, 
prevention, postpartum haemorrhage and randomized trials. The search was conducted 
irrespective of geographical region of the study.  Databases were searched from 
inception till 2011 with no language restrictions. 
The following figure (Figure 1) shows the search strategy conducted on the different 
databases in detail. 
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Figure 1: MEDLINE Database Search Strategy for misoprostol versus placebo citation 
 
2. MEDLINE (Search period inception - 2011) 
1.0 Search randomized controlled trial Field: Publication type 
 
1.1 Search controlled clinical trial Field: Publication type 
 
1.2 Search randomized Field: Title or Abstract 
 
1.3 Search placebo Field: Title or Abstract 
 
1.4 Search drug therapy Field MeSH subheadings 
Misoprostol, cytotec, prostaglandins 
 
1.5 Search randomly Field: Title or Abstract 
 
1.6 Search postpartum bleeding or postpartum haemorrhage OR 
third stage of labour Field: Title or Abstract 
 
1.7 Search Normal vaginal delivery complications 
1.8 Search # 1.3,1.4,1.6 
1.9 Search # 1.3 # 1.6 # & # 1.7 
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Searching other sources:  The following journals were hand searched: British Journal 
of obstetrics and gynaecology, International Journal of Gynaecology and Obstetrics, 
South African Journal of Obstetrics and Gynaecology and British Medical Journal. 
Conference reports (17th Expert Committee on the Selection and Use of Essential 
Medicines Geneva, 2009), The World health report 2005 (WHO, 2005), Route 
of misoprostol administration: Examining efficacy, side effects and acceptability (Gynuity 
Health Projects) were identified.  Drug administration Guidelines from WHO were also 
considered.  There were no ongoing studies found from Clinical trials register. 
 
Data collection and analysis 
 
Selection of studies:  Two reviewers, Kabelo Monicah Olefile (KMO) and Oswell 
Khondowe (OK) independently assessed all potential studies identified as a result of the 
search strategy.  Disagreements were resolved through discussions.  Where consensus 
was not reached, a third reviewer Doreen M’Rithaa (DM) was available. 
 
Data extraction and management:  KMO and OK independently extracted data from 
eligible studies by using a standardised data extraction form that was adapted from the 
Cochrane Collaboration website.  It was adjusted and refined for the purpose of this 
review.  The refined version was piloted and used in the research process by KMO and 
OK.  Data extracted included characteristics of participants, interventions used, length 
of follow-up, outcome measures, blood loss and side effects.  All data was recorded in a 
data collection form.  Data was entered into Review Manager 5.1 (RevMan 5.1) for 
analyses. 
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Assessment of risk of bias in included studies 
KMO and OK independently assessed the validity of the studies by using the criteria 
outlined in Cochrane handbook of systematic reviews of interventions (Higgins, 
2006).the following criterions were assessed: 
 
Random sequence generation (assessment for possible selection bias):  Method 
used to generate allocation sequence in sufficient detail to allow an assessment of 
whether it should produce comparable groups was assessed as follows: 
• Low risk of bias – (any truly random process, e.g. random number table, 
computer random number generator). 
• High risk  of bias – (any non-random process, e.g. odd or even date of birth, 
hospital or clinic number, days of the week, date of admission). 
• Unclear risk of bias. 
 
Allocation concealment (assessment for possible selection bias):  Quality score for 
concealment of allocation to study interventions prior to assignment and whether 
intervention allocation could have been foreseen in advance, during recruitment or 
changed after assignment was assigned using the following criteria: 
• Low risk of bias – (e.g. telephone or central randomisation, consecutively 
numbered sealed opaque envelopes). 
• High risk of bias – (open random allocation, unsealed or non-opaque envelopes, 
alternation, date of birth). 
• Unclear risk of bias. 
 
Blinding of participants, personnel and outcome assessors (assessment for 
possible performance and detection bias):  Studies were considered to be low risk of 
bias if they were blinded.  Methods used to blind participants and personnel from 
knowledge of interventions a participant received were assessed as follows:  
• Low, high or unclear risk of bias for participants. 
• Low, high or unclear risk of bias for personnel. 
• Low, high or unclear risk of bias for outcome assessors. 
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Incomplete outcome data (checking for possible attrition due to the amount, 
nature and handling of incomplete outcome data):  For each included study and 
each outcome, the completeness of data including attrition and exclusion from analysis 
was described.  Whether attrition and exclusions were reported and the numbers 
included in the analysis at each stage (compared with the total number of randomised 
participants), reasons for attrition or exclusion were reported and whether missing data 
was balanced among groups or related to the outcomes were stated.  Loss to follow-up 
was coded in each outcome as follows: 
• Low risk of bias – (no missing outcome data, missing data balanced across 
groups). 
• High risk of bias – (number of reasons for missing outcome data unbalanced 
across groups). 
• Unclear risk of bias. 
 
Selective reporting (checking for reporting bias):  Investigation was done on 
whether there was a possibility of selective outcome reporting bias.  Assessment 
methods were as follows: low risk of bias: 
• Low risk of bias – (where it is clear that all of the study’s pre-specified outcomes 
and all expected outcomes of interest to the review were reported). 
• High risk of bias – (where not all the study’s pre-specified outcomes have been 
reported, one or more primary outcomes were not pre-specified or outcomes of 
interest are reported incompletely and so cannot be used,stuy fails to include 
results of a key outcome that would have been expected to have been reported). 
• Unclear risk of bias. 
 
Other bias (checking for bias due to problems not covered by the above 
criterions):  For each trial, any important concerns about other possible sources of bias 
were described.  Each study was assessed whether it was free from other problems that 
could put it at risk of bias as follows:  
• Low risk of other bias.  
• High risk of other bias. 
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• Unclear risk of other bias. 
 
Overall risk of bias:  Explicit judgement was made about whether studies are at high 
risk of bias, according to the criteria given in the Cochrane handbook.  With reference to 
criterions above, assessment was done on the magnitude and direction of the bias and 
whether it was considered likely to impact on the findings. 
 
Measures of treatment effect:  Results were presented as summary using risk 
ratios (RR) with 95% confidence interval (CI) as the measurement of effect size for 
binary outcomes.  For continuous data, mean difference was to be used if outcomes 
were measured in the same way between trials and standardised mean difference to 
combine trials that measure the same outcome, but used different methods.  Random 
effect (Mantel-Haenszel) meta-analysis was used for were heterogeneous trials.  
Statistical analyses were done using (RevMan 5.1).  
 
Dealing with missing data:  Reviewers proposed to contact original authors in 
cases where data was missing.  However, this was not necessary as all required data 
was obtainable in included articles.  
 
Assessment of heterogeneity:  A test of heterogeneity between trials was 
applied by using a Chi-square test and I2.  An I2 describes the percentage of the 
variability in effect estimates that it is due to heterogeneity rather than sampling error 
(chance) (Higgins, 2003).  If the I² was > 30 to < 60 % it represented moderate 
heterogeneity, > 60 % to < 80% represented substantial heterogeneity and > 80% -
100% was considerable heterogeneity.  We regarded heterogeneity as not important 
when I2 was less than 30%. We regarded heterogeneity as substantial when I2 was 
greater than 30% and either T2 was greater than zero or there was a low P value (less 
than 0.10) in the Chi2 test for heterogeneity. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
14 
 
Assessment of reporting bias:  If there were 10 or more studies in meta analysis, 
reporting bias (such as publication bias) would have been investigated using funnel 
plots.  Funnel plots would have been assessed for asymmetry visually.  If signs of 
asymmetry were detected visually or formally, exploratory analysis investigations would 
have been performed. 
 
Data synthesis:  Meta analysis was carried out using RevMan 5 software.  Meta-
analysis combines the results of two or more studies to increase power and precision, to 
settle controversies arising from conflicting studies and to answer questions which 
individual studies fail to do (Deeks, Altman & Bradburn, and 2006:102).  We used fixed-
effect meta-analysis for combining data where it was reasonable to assume that studies 
were estimating the same underlying treatment effect: i.e. where trials were examining 
the same intervention, and the trials’ populations and methods were judged sufficiently 
similar.  Random effects meta-analysis was incorporated to produce an overall 
summary of effects when sufficient clinical heterogeneity was expected.   When random 
and fixed effects meta analysis was used, summary of results were presented as 
average treatment effect with 95% confidence interval and I2.  Descriptive analysis of 
included and excluded studies was also undertaken. 
 
Subgroup analysis and investigation of heterogeneity:  When substantial 
heterogeneity was identified, it was investigated using sub group analysis. Subgroup 
analysis was done by route of administration of misoprostol (oral and sublingual) based 
on the incidence of PPH. Differences between subgroups were assessed by inspection 
of the subgroups’ confidence intervals.  Non-overlapping confidence intervals indicated 
a statistically significant difference in treatment effect between the subgroups.  If 
sufficient heterogeneity existed, sensitivity analyses would have been performed 
 
Sensitivity analysis:  Sensitivity analyses was planned to incorporate assessment 
of risk of bias in the review process by plotting intervention effects estimates stratified 
for risk of bias for each relevant domain.  In case of differences in results among studies 
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with different risks of bias, we planned to perform sensitivity analysis excluding studies 
with high risk of bias. 
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Results 
Results of the search:  The search yielded 339 articles.  After carefully reading of the 
titles, 294 articles were discarded.  The abstracts of the remaining 45 articles were read 
by two reviewers Kabelo Monicah Olefile (KMO) and Oswell Khondowe (OK) 
independently.  Thirty-six articles were excluded as they did not meet the inclusion 
criteria.  Reasons for exclusion were that articles were reviews, editorials, reporting on 
outcomes not of interest and misoprostol being administered for other obstetrical use 
and misoprostol being compared to other uterotonic drugs.  Full text articles were read 
in the remaining nine articles by the reviewers independently.  This procedure led to 
further exclusion of 5 articles, reason being that misoprostol was compared to placebo 
in addition to other uterotonics.  One trial was further excluded.  This study included 
three articles.  See figure 2 for selection of articles. 
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Figure 2: Flow diagram of electronic search 
 
 
Potentially relevant studies identified and 
screened for retrieval (n=339) 
Studies retrieved for more detailed evaluation 
(n=45) 
Studies excluded, after reading titles 
(n=294) 
-duplicates 
-Reviews 
Studies excluded after reading abstracts 
(n=36). Reviews, case reports, studies 
not reporting on outcome of interest, 
commentaries, books. Misoprostol 
compared to other uterotonic drugs. 
Potentially appropriate studies to be included in the 
systematic review and meta-analysis (n=9) 
Studies included in systematic review (n=3) 
(n=5) Study excluded after full text 
evaluation and  
-interventions used in addition to other 
uterotonic drugs 
 
Articles reporting on the misoprostol vs 
placebo (n=4) 
(n=1) excluded after critical 
methodological assessment. 
-unblinded, outcomes not clearly 
reported, attrition rate of more than 15% 
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Description of studies:  See table 2 for characteristics of included studies and 
appendix 2 for characteristics excluded studies. 
Included studies 
Design:  All included studies were reported RCTs  
Sample size:  The total number of participants included in the trials contributing data to 
this review was 2346 pregnant women, and all of them were included in final analyses. 
The sample size varied from 64 - 1620 participants per trial. 
Setting:  The 3 trials took place in various countries: India, Guinea Bissau and 
Switzerland. 
Participants:  This review includes data for 2346 pregnant women.  Two trials Derman, 
(2006) and Hoj (2005) included pregnant women (with a mean age of 23 years) and 
Suberk (1999) included pregnant women with mean age of 29.3.  
Interventions:  Trials compared the effectiveness of misoprostol compared to a 
placebo for management of third stage of labour in pregnant women with vaginal 
delivery.  Active management of third stage of labour was confirmed in two trials (Hoj, 
2005: Suberk, 1999).  In one trial, Derman (2006) AMTSL components were not fully 
described.  All trials used 600 µg Misoprostol tablets.  Two trials, (Derman, 2006; 
Suberk, 1999) administered Misoprostol orally and in Hoj (2005) Misoprostol was 
administered sublingually.  Treatments interventions were given immediately after the 
delivery of the baby 
Outcomes:  The primary outcome of the 3 trials was incidence of postpartum 
haemorrhage and maternal mortality.  Other outcomes of interests that helped in 
assessment of effectiveness of misoprostol for prevention and treatment of PPH were 
also presented in the trials. 
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 Excluded studies:  Thirty-six of forty-five reports were retrieved for further assessment 
and were excluded to a placebo in addition to other uterotonics.  One trial, Prata, 
Mbaruku, Campbell, Potts and Vahidnia (2005) was further for the reason that 
methodological quality was poor, un-blinded, outcomes not clearly after reading 
abstracts.  Nine studies appeared to be eligible for inclusion in this review.  However we 
excluded five trials after full text examination.  Reasons being:  Misoprostol was 
compared reported, attrition rate of more than 15%, and randomization was not 
described.  See appendix 2 for excluded trials. 
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Table 2: Characteristics of included studies 
Derman, 2006 
Methods  
 
- Randomisation and concealment by computer-generated list with a random block 
size. 
- sealed envelopes 
- double blinding 
Design  - Randomised controlled trial 
Participants  - 1620 pregnant with anticipated, uncomplicated spontaneous vaginal delivery 
Interventions  - 600 µg oral misoprostol versus identical placebo 
-passive management, delayed cord clamping 
Outcomes  - Primary outcome: the incidence of acute postpartum haemorrhage (blood loss ≥500 
mℓ).  
- Secondary outcomes: severe postpartum haemorrhage (blood loss ≥1000 mℓ within 
2 hours of delivery) and mean blood loss, need for transfer to a higher level facility, 
use of additional open-label uterotonic agents, blood transfusion, surgical 
intervention, maternal death, and drug-related maternal and neonatal side-effects 
 
 
 
 
 
Hoj, 2005 
Methods  - Randomisation by opaque envelopes were consecutively 
Numbered 
Design  - Randomised double blind placebo controlled trial. 
Participants  - 661 women undergoing vaginal delivery. 
Interventions   - Misoprostol 600 µg  or identical placebo administered 
Sublingually immediately after delivery. 
-placenta delivered by controlled cord traction (AMTSL). 
Outcomes  - Incidence of PPH ( blood loss of ≥500mℓ) 
- decrease in haemoglobin concentration after delivery 
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Continuation of table 2……….. 
Surbek, 1999 
Methods  - Random allocation with number-generated tables. 
Design  - Randomised double masked placebo-controlled trial 
Participants  - 65 women with anticipated vaginal deliveries 
Interventions   - Oral dose of misoprostol (600 µg) versus identical placebo immediately after cord 
clamping. 
- early cord clamping and cord traction (AMTSL). 
 
Outcomes  - Primary outcome: incidence postpartum blood loss (≥500mℓ) and by antepartum and 
postpartum hematocrit values 
- Secondary outcomes: side effects, additional use  of oxytocics 
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Risk of bias in included studies 
Two Reviewers (KMO & OK) assessed all included trials for risk of bias and were 
blinded to each other’s assessments.  The risk of bias in included studies varied.  All 
trials had no missing data.  All three studies used methods of sequence generation and 
allocation concealment which we assessed as being at low risk of bias and overall, the 
included studies were assessed as low risk of bias for other domains of methodological 
quality.  For an overview of review authors' judgments about each risk of bias item for 
individual included studies, see Figure 3. 
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Figure 3 presents trials The “Risk of bias” assessment done in three trials. 
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Figure 3: Risk of bias summary: review authors' judgments about each risk of bias item for each 
included study. 
 
Key:  
 
 
 
 
 
+ 
Stellenbosch University  http://scholar.sun.ac.za
24 
 
Allocation:  All studies included in this review were reported as being RCTs.  Sample 
size calculation was clearly stated in all three trials.  Adequate sequence generation 
was performed in all included trials and these were rated as 'low risk of bias' (Derman, 
2006, Hoj, 2005 & Suberk, 1999).  All included trials had adequate allocation 
concealment (used sealed opaque envelopes) and were rated as 'low risk of bias'). 
Blinding:  Double-blinding was reported in 3 included trials (Derman, 2006; Hoj, 2005; 
Suberk, 1999).  Personnel and participants were blinded to the intervention given. 
Identical placebos were used.  In Suberk (1999) trial, three identical gelatine capsules, 
each containing misoprostol (200 mg) (Cytotec) or identical placebo was used.  In Hoj 
(2005) and Derman (2006), three tablets of placebo or three 200mg misoprostol tablets 
were used and identical to placebo.   
Incomplete outcome data:  There was no outcome data missing in all included trials. 
An intention-to-treat analysis was used in all.  The rate of losses to follow-up varied from 
0% to 0.25%.  All trials recruited the pre-calculated sample size.  
Selective reporting:  All out comes were reported in all included studies and were all 
rated as low risk of bias. 
Other potential sources of bias:  None identified. 
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Effects of interventions 
 
Comparison: The effectiveness of misoprostol versus a placebo in prevention 
and treatment of postpartum haemorrhage. 
 
Incidence of PPH (Blood loss of ≥500mℓ):  Three studies with a total of 2346 
participants reported on the primary outcome, incidence of PPH as shown below in 
figure 4.  There was a non-significant tendency of blood loss of ≥500mℓ for those who 
received Misoprostol.  The summary of risk ratios of 3 trials regardless of route of 
administration of Misoprostol was RR 0.65 and 95% Confidence Interval (CI) 0.40 to 
1.06.  Misoprostol does not appear to be more effective than a placebo in treatment of 
PPH.  There was a high level of heterogeneity amongst the studies (p=0.008), I2= 79%. 
Subgroup analysis on the route of administration was conducted to explore 
heterogeneity. 
 
Figure 4: Random effect analysis  of Misoprostol versus a placebo in prevention and treatment of 
PPH on incidence of PPH.  
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Subgroup analysis was done on the route of administration of misoprostol among trials. 
Route can be a confounding factor.  Although oral and sublingual routes have the 
advantage of rapid onset of action, sublingual has the most enhanced bioavailability.  In 
comparison of the two routes of administration, oral route was associated with a 
decreasing the incidence of PPH (RR 0.52, 95%CI 0.38-0.72) compared to sublingual 
(RR 0.89, 95% CI 0.76-1.04).  We did not conduct sensitivity analyses because all 
included trials for this outcome were rated as ’low risk of bias’ for allocation of 
concealment. 
 
Need for blood transfusion:  Only one trial, Derman et al (2006) reported on the need 
for blood transfusion.  The study found no significant difference in need for blood 
transfusion between participants who got Misoprostol and placebo (RR 0.14 CI 95% 
0.02 - 1.15).  Meta analysis was not performed. 
 
Hysterectomy/surgery:  Only one trial (Derman et al 2006) reported on hysterectomy 
or major surgery.  The overall effect of misoprostol was coupled with a reduced rate of 
hysterectomy/surgery compared to a placebo (RR 0.12, CI 95% 0.02-0.99).  Meta 
analysis was not performed. 
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Pyrexia:  Figure 5 below illustrates the occurrence of pyrexia in two trials.  There were 
1142 women who received Misoprostol and 1139 women who received a placebo.  
Meta analysis evaluating the occurrence of pyrexia revealed a statistical significant 
difference between the two groups (summary of RR was 5.34 (95%CI 2.86-9.96).  
There was evidence of significant heterogeneity among results of studies included for 
the outcome pyrexia (p=0.19), I2=42%. 
 
Figure 5: Random effect analysis of Misoprostol versus a placebo in prevention and treatment of 
PPH on Pyrexia 
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Shivering: There was no statistically significant difference in shivering between 
participants who received Misoprostol compared to those who received placebo.  
Misoprostol was not associated with a significant lessening of shivering RR 2.75 (95%CI 
2.26 – 3.34).  There was some evidence of statistical heterogeneity detected in studies 
(p=0.21), I2=36%.   
 
 
Figure 6: Random effect analysis of Misoprostol versus placebo in prevention and treatment of 
PPH on shivering. 
 
Need for additional uterotonics:  Figure 7 below shows results of two studies.  
Misoprostol was associated with reduction in need for additional uterotonics compared 
to a placebo (RR 0.45, 95% CI 0.21- 0.96, p=0.04).  The trials were homogeneous 
(chi²=0.04, I²=0%, p=0.84) and there was a significant difference among all the studies 
as they strongly favored misoprostol with risk ratio of less than 1.  
Study or Subgroup
Derman, 2006
Surbek, 1999
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 2.07 (P = 0.04)
Events
3
5
8
Total
812
31
843
Events
6
13
19
Total
808
34
842
Weight
32.7%
67.3%
100.0%
M-H, Fixed, 95% CI
0.50 [0.12, 1.98]
0.42 [0.17, 1.05]
0.45 [0.21, 0.96]
Experimental Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
 
Figure 7: Fixed effect analysis of Misoprostol versus  a placebo in prevention and treatment of 
PPH on need for additional uterotonics. 
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Conclusion of results 
There was significant heterogeneity among results of studies on route of administration. 
In sub grouping of the two routes, Misoprostol administered orally does show a 
significant reduction in postpartum blood loss compared to sublingual route.  Side 
effects, pyrexia and shivering were persistent in the Misoprostol group but are dose 
related. Maternal mortality and manual removal of placenta were not reported in all 
studies (n=3). 
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Discussion 
Summary of main results 
This review included comparison of misoprostol and placebo for management of third 
stage of labour without additional uterotonics.  Meta analysis was done on results of 
three included studies.  Misoprostol was administered orally and sublingually. Most 
clinically relevant outcomes that this review focused on were the incidence of PPH, 
occurrence of side effects and additional use of other uterotonics.  In overall, 
Misoprostol did not show a significant reduction of PPH.  However there was significant 
heterogeneity in the results of blood loss.  Heterogeneity of results may be because of 
different route of administration of misoprostol.  Most blood loss was shown in Hoj 
(2005) trial.  In sub grouping of these trials by route of administration, oral route showed 
a significance reduction in incidence of postpartum haemorrhage compared to 
sublingual route in Hoj (2005) trial.  
 
The incidence of PPH in this review is consistent with results of trial of Hofmeyr et al 
2007, where misoprostol was associated with a trend of reduced blood loss ≥500 ml, 
but this dramatic effect couldn’t be confirmed as the lower incidence of PPH in placebo 
group  underpowered this result.  None of the trials reported on maternal mortality and 
manual removal of placenta.  There was no evidence to support the benefit of 
misoprostol in reduction of need for blood transfusion as there was only one trial that 
reported on blood transfusion.  There was a consistent increase in pyrexia across two 
trials (Hoj, 2005; Derman, 2006) mostly in misoprostol arm. Shivering was also 
consistent among all included trials.  These radical rates of side effects are concluded in 
other trials as been dose related (Amant, Spitz, Timmerman, Corremans and van 
Assche (1999) and El Refaey, O’Brien, Morafa, Walder and Rodeck (1997). 
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These side-effects may be related to the rapid absorption of misoprostol given orally, 
rapid absorption and high bioavailability when given sublingually.  There was a 
significant decrease in need for additional uterotonics with misoprostol use.  Studies 
were homogenous and there was no heterogeneity among them. While there was a 
statistically significant decrease in cases of hysterectomy with misoprostol use, results 
for this outcome should be interpreted with caution as heterogeneity could not be 
measured as only one study that reported on this outcome. 
 
Overall completeness and applicability of evidence 
This review was to discover if Misoprostol is more effective than placebo in prevention 
and treatment of PPH.  All relevant literature was retrieved from published journals.  
There are no ongoing studies at present moment.  The included studies concentrated 
on how effective Misoprostol is and body of evidence does apply to the research 
question.  The three trials were conducted in community hospital settings where 
deliveries were conducted by midwives.  Participants were similar across the trials, 
which made it more comparable.  All main outcomes of interest were presented in trials 
but not all sub-outcomes were presented.  Misoprostol was compared to a placebo in all 
trials. In two trials (Høj, 2005; Suberk, 1999) active management was done and in 
Derman (2006), passive management of third stage of labour was confirmed. 
 
Quality of evidence 
All of the studies (3 of 3) had good quality evidence (low risk of bias for sequence 
generation and allocation concealment).  Sequence generation, blinding and allocation 
concealment was clearly explained in all trials.  Reviewers could not assess selective 
reporting; however the primary outcomes of this review were addressed across all the 
trials.  Showing both absolute and relative measures for each outcome is a more 
transparent evaluation of data, considering the different weight that several variables 
have on such measures.  We accomplished such a need by reporting both RR. 
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Potential biases in the review process 
All relevant studies were identified.  A comprehensive search of more than one 
database for RCTs was implemented to minimize selection bias. Potential bias can 
result when databases have published only trials that there feel will suit their database. 
We followed methods set out in the Cochrane Handbook (Higgins 2003) to try to reduce 
bias in the review process.  The review is not able to provide data about the possible 
biasing effect of protocol violations on the results as we did not have actual protocols of 
trials. The review only considered published trials hence other trials that are not 
published that may benefit and alter results of this review may be left out. 
 
Agreements and disagreements with other study reviewers 
A Cochrane review by Gulmezoglu et al (2011) entitled “prostaglandins for preventing 
Postpartum haemorrhage” also carried out meta analysis on the effectiveness of 
misoprostol compared to a placebo.  The results of this review are in agreement with 
the above mentioned review on the incidence of PPH when misoprostol is administered 
orally.  However, in their review, they compared studies that used misoprostol in 
addition to other uterotonics unlike in this review where meta analysis was done only in 
studies that compared misoprostol without additional uterotonics.  The true benefit of 
misoprostol in prevention and treatment of third stage of labour can only be revealed 
when misoprostol is used alone not combined with the effect of other uterotonics. 
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Authors’ conclusions 
 
Implications to research 
Future randomized controlled trials are required to identify the best route, and dose of 
misoprostol, for the treatment of primary PPH. Side effects (pyrexia and shivering) 
associated with Misoprostol are dose related and should be watched carefully. Home 
deliveries in some communities are still evident.  It is vital to investigate on interventions 
to control of PPH following home deliveries.  More importantly, trials must be large 
enough to assess maternal morbidity and mortality.  There has being a lack of research 
linking management of the third stage of labour to what has occurred in the first and 
second stages of labour.  It may be timely to assess possible effects of current 
strategies for management of labour on rates of PPH.  None of the included trials has 
addressed the women’s preferences, associated with uterotonic options.  It would be of 
interest to embrace this aspect of care in future research on trials of uterotonic choice. 
  
Limitations 
The review focused mainly on studies that compared misoprostol to a placebo, not in 
addition to other uterotonics, hence only three trials included for analysis.  This may 
result in other studies that tested misoprostol to a placebo to be left out, which could 
have benefitted on the findings of this review.  
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Conclusion 
 
The overall use of misoprostol was not associated with any significant reduction in 
amount of blood loss.  Studies included in the review were not large enough to evaluate 
the effects of misoprostol on maternal mortality, in women with primary PPH.  Because 
of the enormous potential impact of PPH on maternal health in poor countries, further 
research aiming to evaluate effects of misoprostol on substantive health outcomes, its 
safety and the optimal route and dosage is of the utmost urgency.  Misoprostol is 
relatively cheap easy to administer compared to injectable uterotonics (oxytocin, 
ergometrine) of which are considered first line of treatment by WHO.  Ergometrine and 
syntometrine are contraindicated in hypertensive pregnant women as they stimulate 
vasoconstriction and causes hypertension.  Injectable uterotonics need skill to 
administer, sterile syringes, alcohol swabs, unstable in tropical conditions and requires 
special storage facilities to maintain efficacy, whereas Misoprostol is devoid of these 
constraints and may therefore be an alternative treatment of in developing countries 
where storage facilities and resources are limited. 
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Appendix 1 : Data extraction form 01 
1. Source 
Study ID  Derman, 2006 
Reviewer  Kabelo Monicah Olefile; Oswell Khondowe 
Author & year  Derman, R.J, Kodkany, B.S., Goudar, S.S., Geller, S.E., Naik, 
V.A., Bellad, M. B., Patted, S.S., Patel, A., Edlavitch, S.A., 
Hartwell, T., Chakraborty, H. & Moss,N., 2006 
Journal  Lancet; 368: 1248–53.,  
Title  Oral misoprostol in preventing postpartum haemorrhage in 
resource-poor communities: a randomised controlled trial 
Country  India  
 
2. Eligibility 
(Tick in the appropriate spaces) 
2.1 Types of studies 
RCT √ 
Quasi-experimental - 
Published study √ 
 
2.2 Types of participants 
Term pregnancy √ 
Spontaneous vaginal deliveries √ 
Caesarean section - 
 
 
2.3 Types of intervention 
(Tick in the appropriate spaces and provide details of treatment given) 
Treatment   Details  
Misoprostol vs placebo √ 600µg orally  
Misoprostol vs placebo in addition to other uterotonics - - 
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2.4 Types of outcomes 
Incidence of PPH (blood loss 
≥500mℓ) 
 √ 
Maternal mortality √ 
Need for Blood transfusion √ 
Hysterectomy/Surgery √ 
Manual removal of placenta  
Pyrexia √ 
Shivering  
√ 
Need for Additional uterotonics √ 
   
2.5 Participants lost to follow-up <15% 
Total number of participants Total number lost % lost 
1620 4 0.25% 
 
 
2.5.1 Reasons for loss to follow-up 
3 participants did not receive misoprostol 
 
Reasons: patient  transferred, twin delivery, and excess bleeding 
1 did not receive placebo  
 
Reason: stillbirth 
 
2.5.2 Other reasons for exclusion 
None. 
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Methodology 
3.1 Study design 
RCT √ Multi centre √ 
Quasi-experimental - Single centre  
 
 
3.2 Duration of Study 
Months  39 months 
 
3.3 Eligibility Criteria 
-pregnant women with uncomplicated spontaneous vaginal delivery. 
-more than 28 weeks pregnant. 
-no chronic diseases. 
 
 
 
 
Methodological quality/ risk of bias assessment 
(Answer the domain question with “LR” signifying low risk of bias, “HR” signifying high 
risk of bias, “U” signifying lack of information or unknown risk of bias). 
3.4 Cochrane collaboration “Risk of bias” Tool 
Entry  Judgement description 
Adequate sequence generation? LR Computer generated 
randomization 
Allocation concealment? LR Non-distinguishable envelops with 
drug of same appearance. 
Blinding of participants, 
personnel and outcome 
assessors? 
LR Preparation of envelops by 
independent pharmacist. 
Personnel & participants blinded. 
Incomplete outcome data 
addressed? 
LR No data was missing 
Selective outcome reporting? LR Reported on all outcomes 
Other bias? LR Conflict of interest declared 
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3.5 Participants 
Total number  1620 
Total number analyzed 1620 
Single or twin pregnancy Single 
Mode of delivery Vaginal delivery 
High risk or low risk Low risk 
Study setting Sub centre of health. 
Age of participants (mean) 23.2 
Sex  Females  
Country India  
 
3.6 Interventions 
Experimental group 
Type  Route Dose Time given 
Misoprostol  orally 600µg Within 5 minutes of 
clamping and cutting of 
the umbilical cord 
Control group 
Type  Route Dose Time given 
Placebo  Orally 600µg Within 5 minutes of 
clamping and cutting of 
the umbilical cord 
 
3.7 Outcomes relevant to this review 
(Tick where appropriate) 
Incidence of PPH (blood loss ≥500mℓ) YES√ NO 
Maternal mortality YES√ NO 
Need for Blood transfusion YES√ NO 
Hysterectomy/Surgery YES√ NO 
Manual removal of placenta YES√ NO 
Pyrexia YES√ NO 
Shivering YES√ NO 
Need for Additional uterotonics YES√ NO 
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4. Results 
Total number of participants 
 Total 
Randomised 
Total included in analysis 
Experimental arm 812 812 
Control arm 808 808 
Total  1620 1620 
 
 
4.1 summary data for each intervention group 
Outcomes  Intervention groups 
E C 
E T E T 
Incidence of PPH (blood loss 
≥500mℓ) 
52 812 97 808 
Maternal mortality 0 812 0 808 
Need for Blood transfusion 1 812 7 808 
Hysterectomy/Surgery 1 812 8 808 
Manual removal of placenta 0 812 0 808 
Pyrexia 34 812 9 808 
Shivering 419 812 140 808 
Need for Additional uterotonics 3 812 6 808 
 
4.2 Continuous data: N/A 
4.3 Subgroup analysis 
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Appendix 2:  Data extraction form 02 
1. Source 
Study ID  Suberk,1999 
Reviewer  Kabelo Monicah Olefile, Oswell Khondowe 
Author & year  Suberk, D.V., Fehr, P.M., Hösli, I. & Holzgreve, W. 1999. 
Journal  Elsevier Science Incorporation; 92: 255-258. 
Title  Oral Misoprostol for Third Stage of Labor: A Randomized Placebo-
Controlled Trial 
Country  Switzerland 
 
2. Eligibility 
(Tick in the appropriate spaces) 
2.1 Types of studies 
RCT √ 
Quasi-experimental - 
Published study √ 
 
2.2 Types of participants 
Term pregnancy √ 
Spontaneous vaginal deliveries √ 
Caesarean section - 
 
2.3 Types of intervention 
(Tick in the appropriate spaces and provide details of treatment given) 
Treatment  Details  
Misoprostol vs placebo √ 600µg orally 
Misoprostol vs placebo in addition to other uterotonics - - 
 
2.4 Types of outcomes 
Incidence of PPH (blood loss 
≥500mℓ) 
√ 
Maternal mortality √ 
Need for Blood transfusion - 
Hysterectomy/Surgery - 
Manual removal of placenta - 
Pyrexia - 
Shivering - 
 
Need for Additional uterotonics √ 
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  2.5 Participants lost to follow-up <15% 
Total number of participants Total number lost % lost 
65 0 0% 
 
2.5.1 Reasons for loss to follow-up 
None applicable 
 
 
Methodology 
3.1 Study design 
RCT √ Multi centre - 
Quasi-experimental - Single centre √ 
 
3.2 Duration of Study 
Months  11 months 
 
3.3 Eligibility Criteria 
Women with anticipated vaginal deliveries. 
 
 
 
 
 
 
Methodological quality/ risk of bias assessment 
(Answer the domain question with “LR” signifying low risk of bias, “HR” signifying high 
risk of bias, “U” signifying lack of information or unknown risk of bias). 
3.4 Cochrane collaboration “Risk of bias” Tool 
Entry  Judgement description 
Adequate sequence generation? LR Random generated tables 
Allocation concealment? LR Study drugs allocation prepared by 
hospital pharmacy. 
Identical drug capsules. 
Blinding of participants, 
personnel and outcome 
assessors? 
LR Randomisation code not broken till 
completion of study. Participants and 
midwives unaware of treatment 
allocation. 
Incomplete outcome data 
addressed? 
LR No missing data 
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Selective outcome reporting? LR Reported on all outcomes 
Other bias? Unclear  None  
 
3.5 Participants 
Total number  65 
Total number analyzed 65 
Single or twin pregnancy single 
Mode of delivery Vaginal delivery 
High risk or low risk Low risk 
Study setting Hospital setting 
Age of participants (mean) 29.3 
Sex  Female  
Country Switzerland  
 
3.6 Interventions 
Experimental group 
Type  Route Dose Time given 
Misoprostol  Orally  600 mg Immediately after cord 
clamping 
Control group 
Type  Route Dose Time given 
Placebo  Orally  600 mg Immediately after cord 
clamping 
 
3.7 Outcomes relevant to this review 
(Tick where appropriate) 
Incidence of PPH (blood loss ≥500mℓ) YES√ NO 
Maternal mortality YES√ NO 
Need for Blood transfusion YES NO 
Hysterectomy/Surgery YES NO 
Manual removal of placenta YES NO 
Pyrexia YES NO 
Shivering YES NO 
Need for Additional uterotonics YES√ NO 
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4. Results 
Total number of participants 
 Total 
Randomised 
Total included in analysis 
Experimental arm 31 31 
Control arm 34 34 
Total  65 65 
 
4.1 summary data for each intervention group 
 
Outcomes  Intervention groups 
E C 
E T E T 
Incidence of PPH (blood loss 
≥500mℓ) 
2 31 7 34 
Maternal mortality 0 31 0 34 
Need for additional uterotonics 5 31 13 34 
 
4.2 Continuous data: N/A 
4.4 Subgroup analysis: N/A 
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Appendix 3:  Data extraction 03 
1. Source 
Study ID  Hoj,2005 
Reviewer  Kabelo Monicah Olefile: Oswell Khondowe 
Author & year  Hoj, L., Cardoso, P., Nielsen, B.B., Hvidman, L., Nielsen, J. & 
Aaby, P. 2005.  
Journal  British Medical Journal; 331: 723. 
Title  Effect of sublingual misoprostol on severe postpartum 
haemorrhage in a primary health centre in Guinea-Bissau: 
randomised double blind clinical trial 
Country  Guinea-Bissau 
 
2. Eligibility 
(Tick in the appropriate spaces) 
2.1 Types of studies 
RCT √ 
Quasi-experimental - 
Published study √ 
 
2.2 Types of participants 
Term pregnancy - 
vaginal deliveries √ 
Caesarean section - 
 
 
2.3 Types of intervention 
(Tick in the appropriate spaces and provide details of treatment given) 
Treatment  Details  
Misoprostol vs placebo √ 600µg 
misoprostol 
Misoprostol vs placebo in addition to other uterotonics - - 
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2.4 Types of outcomes 
Incidence of PPH (blood loss 
≥500mℓ) 
√ 
Maternal mortality √ 
Need for Blood transfusion - 
Hysterectomy/Surgery - 
Manual removal of placenta - 
Pyrexia √ 
Shivering  
√ 
Need for Additional uterotonics - 
   
2.5 Participants lost to follow-up <15% 
Total number of participants Total number lost % lost 
661 0 0% 
 
 
Methodology 
3.1 Study design 
RCT √ Multi centre - 
Quasi-experimental - Single centre √ 
 
3.2 Duration of Study 
Months  17 months 
 
Methodological quality/ risk of bias assessment 
(Answer the domain question with “LR” signifying low risk of bias, “HR” signifying high 
risk of bias, “U” signifying lack of information or unknown risk of bias). 
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3.4 Cochrane collaboration “Risk of bias” Tool 
Entry  Judgement description 
Adequate sequence generation? LR Random blocked sizes were 
used. (computer-generated 
Randomisation) 
Allocation concealment? LR Pharmacy controlled 
randomization, opaque 
envelopes. 
Identical tablets in form, 
size and color. 
Blinding of participants, personnel and 
outcome assessors? 
LR Double blinding 
Incomplete outcome data addressed? LR No data missing. 
Selective outcome reporting? LR Reported on all mentioned 
outcomes. 
Other bias? LR Conflict of interest declared. 
 
3.5 Participants 
Total number  661 
Total number analyzed 661 
Single or twin pregnancy Single  
Mode of delivery Vaginal delivery 
High risk or low risk Low risk 
Study setting Local health centre 
Age of participants (mean) 23yrs 
Sex  Females  
Country Guinea-Bissau 
 
3.6 Interventions 
Experimental group 
Type  Route Dose Time given 
Misoprostol  sublingually 600µg immediately after 
delivery 
Control group 
Type  Route Dose Time given 
Placebo  sublingually 600µg immediately after 
delivery 
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3.7 Outcomes relevant to this review 
(Tick where appropriate) 
Incidence of PPH (blood loss ≥500mℓ) YES√ NO 
Maternal mortality YES√ NO 
Need for Blood transfusion YES NO√ 
Hysterectomy/Surgery YES NO√ 
Manual removal of placenta YES NO√ 
Pyrexia YES√ NO 
Shivering YES√ NO 
Need for Additional uterotonics YES NO√ 
   
4. Results 
Total number of participants 
 Total 
Randomised 
Total included in analysis 
Experimental arm 330 330 
Control arm 331 331 
Total  661 661 
 
4.1 summary data for each intervention group 
Outcomes  Intervention groups 
E C 
E T E T 
Incidence of PPH (blood loss 
≥500mℓ) 
150 330 170 331 
Maternal mortality 0 330 0 330 
pyrexia 78 330 11 331 
Shivering  189 330 78 331 
4.2 Continuous data: N/A 
 
4.3 Subgroup analysis 
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Appendix 4: Table of excluded studies 
Citation  Reasons for exclusion 
Abdel-Aleem, H., El-Nashar, I. & Abdel-Aleem, A. 2001. Management of 
severe postpartum hemorrhage with misoprostol. International Journal of 
Gynecology & Obstetrics; 72: 75-76. 
Short brief. 
Adekanmi, O.A., Purmessur, S., Edwards, G. & Barrington, J.W. 2001. 
Intrauterine misoprostol for the treatment of severe recurrent atonic 
secondary postpartum haemorrhage. British Journal of Obstetrics and 
Gynaecology; 108: 541-542. 
Case report. 
Afolabi, E.O., Kuti, O., Orji, E. O. & Ogunniyi, S. O. 2010. Oral misoprostol 
versus intramuscular oxytocin in the active management of the third stage of 
labour. Singapore Medical Journal; 51: 207-211. 
Interventions not of interest. 
Ahmed, N., Ahmed, Y., Shahin, A. M., Elsamman, M.S. Zakherah, O. & 
Shaaban, O. 2009. Rectal misoprostol versus intravenous oxytocin for 
prevention of postpartum hemorrhage. International Journal of Gynecology 
and Obstetrics 105: 244–247. 
Interventions not of interest. 
Amant, F., Spitz, B., Timmerman, D., Corremans, A. & van Assche, F.A. 
1999. Misoprostol compared with methylergometrine for the prevention of 
postpartum haemorrhage: A double-blind randomized trial. British Journal of 
Obstetrics and Gynaecology; 106(10):1066–70. 
Misoprostol compared to ergometrine. 
Blum, J., Winikoff, B., Raghavan, S., Dabash, R., Ramadan, M.R., Dilbaz, 
B., Dao, B., Durocher, J., Yalvac, S., Diop, A., Dzuba, I.G. & Ngoc, N.T. 
Misoprostol compared to oxytocin, not placebo. 
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2010. Treatment of post-partum haemorrhage with sublingual misoprostol 
versus oxytocin in women receiving prophylactic oxytocin: a double-blind, 
randomised, non-inferiority trial. Lancet; 375: 217–23. 
Blum, J., Alfirevic, Z., Walraven, G., Weeks, A. & Winikoff, B. 2007. 
Treatment of postpartum Haemorrhage with Misoprostol. International 
Journal of Gynecology & Obstetrics; 99: 202-205. 
A systematic review. 
Bugalho, A., Daniel, A., Faundes, A. & Cunha, M. Misoprostol for prevention 
of postpartum hemorrhage. International Journal of Gynaecology Obstetrics; 
73: 1–6. 
Misoprostol compared to oxytocin, not placebo 
Campbell, M.R. & Graham, W.J. 2006. Strategies for reducing maternal 
mortality: Getting on with what works. Lancet; 368: 1284–99. 
A comment. 
Carroli, G. 2002. Side effects of oral misoprostol during the first 24 hours 
after administration in the third stage of labour. British Journal of Obstetrics 
& Gynaecology; 109:1222–26. 
Outcomes not of interest. 
Cook, C.M., Spurrett, B. & Murray, H. 1999. A randomized clinical trial 
comparing oral misoprostol with synthetic oxytocin or syntometrine in the 
third stage of labour. Australia and New Zealand Journal of Obstetrics & 
Gynaecology; 39:414–9. 
Misoprostol compared to oxytocin, not placebo 
El-Refaey, H., O’Brien, P., Morafa, W., Walder, J. & Rodeck, C. 1997. Use of 
oral misoprostol in the prevention of postpartum haemorrhage. British 
Journal of Obstetrics & Gynaecology; 104:336 –9. 
Misoprostol 
El-Refaey, H., Nooh, R., O’Brien, P., et al. 2000.The misoprostol third stage Misoprostol compared to standard treatment. 
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of labour study: A randomised controlled comparison between orally 
administered misoprostol and standard management British Journal of 
Obstetrics and Gynaecology; 107: 1104–10. 
Fawcus, F. & Moodley, J. 2011. Management of postpartum haemorrhage. 
South African Journal of Obstetrics & Gynaecology; 17: 1-2. 
An editorial. 
Fawole, A.O., Sotiloye, O.S., Hunyinbo, K.I., Umezulike, A.C., Okunlola, 
M.A., Adekanle, D.A., et al 2010. Misoprostol and routine uterotonics for 
prevention of postpartum hemorrhage: A double-blind, randomized, placebo 
controlled trial. International Journal of Gynecolology & Obstetrics; 112:107–
111. 
Misoprostol compared to routine uterotonics. 
Hofmeyr, G.J., Fawole, B., Mugerwa, K., Godi, P., Blignaut, Q., Mangesi, L, 
Singata, M., Brady, L., Blum, J. 2010. Administration of 400 µg of 
misoprostol to augment routine active management of the third stage of 
labor. International Journal of Gynecology and Obstetrics; 112: 98–102. 
Misoprostol compared to routine management of 
PPH. 
Hofmeyr, G.J., Ferreira, S. & Nikodem, V.C. 2004. Misoprostol for treating 
postpartum haemorrhage: A randomized controlled trial. BioMedical 
Centre Pregnancy Childbirth.  4: 16 
Misoprostol compared to a placebo in addition to 
other uterotonics. 
Hofmeyr, G. J., Walraven, G. & Gülmezoglu, A.M. 2007. Misoprostol to treat 
postpartum haemorrhage: A systematic review. Journal of Obstetrics& 
Gynecology.  112: 547–553. 
A systematic review. 
Hofmeyr, G.J., Nikodem, V.C., de Jager, M. & Drakely, A.  2001. Side-effects 
of oral misoprostol in the third stage of labour—a randomised placebo-
Misoprostol compared to a placebo in addition to 
other uterotonics 
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controlled trial. South African Medical Journal; 91: 432–35. 
Hofmeyr, G.J., Nikodem, V.C., de Jager, M. & Gelbart, B.R. 1998. A 
randomised placebo controlled trial of oral misoprostol in the third stage of 
labour. British Journal of Obstetrics & Gynaecology; 105:971–5. 
Misoprostol compared to a placebo in addition to 
other uterotonics. 
Kundodyiwa, T.W., Majoko, F. & Rusakaniko S. 2001. Misoprostol versus 
oxytocin in the third stage of labor. International Journal of Gynaecology and 
Obstetrics; 75: 235–41. 
A preliminary report. 
Langenbach C. 2006. Misoprostol in preventing postpartum hemorrhage: A 
meta-analysis. International Journal of Gynaecology and Obstetrics; 92: 10–
18. 
A systematic review. 
Lokugamage, A. U., Sullivan, K.R., Niculescu, O., Tigere, P., Onyangunga, 
F., El- Refaey, H., Moodley, J. & Rodeck, C. 2001. A randomized study 
comparing rectally administered misoprostol versus Syntometrine combined 
with an oxytocin infusion for the cessation of primary post partum 
hemorrhage. Acta Obstetrics & Gynecology Scandinavica; 80: 835–839. 
Misoprostol compared to other uterotonics. 
Lombaard, H., & Pattison, R.C. (2009). Common errors and remedies in 
managing Postpartum Haemorrhage: Maternal and Fetal Medicine Unit, 
Department of obstetrics & Gynecology, University of Pretoria, 1-10. 
Irrelevant and does not report on outcomes of 
interest. 
Miller, S., Lester, F. & Hensleigh, P., (2004). Prevention and treatment of 
postpartum hemorrhage: New advances for low-resource settings. Journal of 
Midwifery Women’s Health, 49: 283-92.  
Does not report on outcomes of interest. 
McCormick, M. L., Sanghvi, H.C., Kinzie, B., & McIntosh, N. 2002. Review article. 
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Preventing postpartum haemorrhage in low-resource settings. International 
Journal of Gynecology and Obstetrics; 77: 267–75. 
Mousa, H. A., Cording, V., & Alfirevic, Z. 2008. Risk factors and interventions 
associated with major primary postpartum hemorrhage unresponsive to first-
line conventional therapy. Acta Obstetric Gynecology, 87: 652–661. 
Does not report on outcomes of interest. 
Ng, P.S., Chan, A.S., Sin, W.K., Tang, L.C., Cheung, K.B., & Yuen, P.M. 
2001.A multicentre randomized controlled trial of oral misoprostol and 
intramuscular syntometrine in the management of the third stage of labour. 
Human Reproduction; 16: 31–35. 
Misoprostol compared to syntometrine. 
Prendiville, W.J., Elbourne, D. & McDonald, S. 2000. Active versus 
expectant management in the third stage of labour. Cochrane Database 
Systematic Review; Issue (3):CD000007. 
Interventions not of interest. 
Prendiville, W.J. 1996. The prevention of postpartum haemorrhage: 
Optimizing routine management of the third stage of labour. European 
Journal of Obstetrics, Gynecology & Reproductive Biology, 69: 19-24.  
Interventions not of interest. 
Sadiq, S.S., Hasmi, U., Aman, Q. & Zareen, N. 2008.Prophylactic use of 
oxytocin (syntoncinon) vs oxytocin plus ergometrine (syntometrine) for 
prevention of postpartum haemorrhage. Pakistan Journal of Surgery, 24: 
235- 239.  
Interventions not of interest 
Singh, G., Radhakrishnan, G. & Guleria, K. 2009. Comparison of sublingual 
misoprostol, intravenous oxytocin, and intravenous methylergometrine in 
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Appendix 4: Prisma Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, 
or both.  
1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal 
and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review 
registration number.  
1 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what 
is already known.  
7 
Objectives  4 Provide an explicit statement of questions being 
addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
7 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
Not 
registered 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of 
follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
8 
Information sources  7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
8 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
9 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
9 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., 
piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from 
investigators.  
11 
Data items  11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
41 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
23 
Stellenbosch University  http://scholar.sun.ac.za
62 
 
information is to be used in any data synthesis.  
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, 
difference in means).  
14 
Synthesis of results  14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
14 
 
 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
23 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity 
or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
15 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8,20 
Study 
characteristics  
18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
23 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).  
12,23,35 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, 
for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
20,36 
Synthesis of results  21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.  
25 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across 
studies (see Item 15).  
17 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity 
or subgroup analyses, meta-regression [see Item 16]).  
23 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and 
policy makers).  
34 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
34 
Conclusions  26 Provide a general interpretation of the results in the 
context of other evidence, and implications for future 
research.  
33 
FUNDING   
Funding  27 Describe sources of funding for the systematic 
review and other support (e.g., supply of data); 
N/A 
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role of funders for the systematic review.  
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